Results 1 to 10 of about 311 (93)
The role of erenumab in the treatment of migraine [PDF]
Therapeutic Advances in Neurological Disorders, 2020 Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first class of specifically developed preventive treatments for migraine. Clinical trials data suggest superiority of the CGRP mAbs to placebo in terms of prevention of migraine symptoms, migraine-specific quality of life and headache related disability. Treatment-related
Giorgio Lambru, Anna Andreou
exaly +5 more sources
Brain Sciences, 2021 Background: We aimed to assess the differences between menstrual and non-menstrual headache in women with chronic migraine treated with erenumab. Methods: We included fertile women from a single center.
Raffaele Ornello +5 more
doaj +1 more source
Hospital Pharmacy, 2018 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Kalvin, Stoker, Danial E, Baker
openaire +2 more sources
Association between response to triptans and response to erenumab: real-life data
The Journal of Headache and Pain, 2021 Background Triptans and erenumab are both migraine-specific agents acting on the calcitonin gene-related peptide pathway. Therefore, response to triptans might be associated with response to erenumab.
Ilaria Frattale +14 more
doaj +1 more source
Erenumab effectiveness and safety: comparison of real-life data and clinical trial results
Neurologijos seminarai, 2021 Background. Erenumab was the first preventive medication targeted to the pathogenesis of migraine to reach Lithuanian market. Previously, evidence of the safety and efficacy of erenumab was supported only by clinical study results, but more recently ...
Austėja Dapkutė , K. Ryliškienė
doaj +1 more source
Pain and Therapy, 2021 Introduction Erenumab is indicated for migraine preventive treatment in adults. The objective of this study was to provide descriptive information on real-world use of erenumab including patient profile and treatment patterns.
David Chandler +4 more
doaj +1 more source
Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
BMC Neurology, 2022 Background Erenumab is a fully human monoclonal antibody and a highly potent, first-in-class calcitonin gene-related peptide receptor inhibitor approved for migraine prevention in adults. Randomised, placebo-controlled trials show that erenumab treatment
Taoufik Alsaadi +4 more
doaj +1 more source
Frontiers in Neurology, 2023 BackgroundTherapeutic options for migraine prevention in non-responders to monoclonal antibodies (mAbs) targeting Calcitonin Gene-Related Peptide (CGRP) and its receptor are often limited.
Lucas Hendrik Overeem +11 more
doaj +1 more source
The Journal of Headache and Pain, 2022 Background Erenumab, a fully human monoclonal antibody that targets the calcitonin gene-related peptide receptor, has demonstrated efficacy and safety in the prevention of episodic and chronic migraine.
Christian Lampl +8 more
doaj +1 more source
The Journal of Headache and Pain, 2022 Background Migraine involves central and peripheral nervous system mechanisms. Erenumab, an anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody with little central nervous system penetrance, is effective for migraine prevention.
Todd J. Schwedt +5 more
doaj +1 more source